DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
| Revenue (TTM) | $5.10B |
| Gross Profit (TTM) | $3.24B |
| EBITDA | $1.50B |
| Operating Margin | 24.30% |
| Return on Equity | 37.70% |
| Return on Assets | 11.10% |
| Revenue/Share (TTM) | $13.36 |
| Book Value | $6.80 |
| Price-to-Book | 12.42 |
| Price-to-Sales (TTM) | 5.80 |
| EV/Revenue | 6.09 |
| EV/EBITDA | 18.43 |
| Quarterly Earnings Growth (YoY) | 2.60% |
| Quarterly Revenue Growth (YoY) | 11.20% |
| Shares Outstanding | $372.95M |
| Float | $371.58M |
| % Insiders | 0.26% |
| % Institutions | 107.88% |
Volatility is currently expanding
DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.
DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,.
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DXCM and any ticker you trade — then tracks every position and per-strategy win rate.
